Most analyst forecasts do not factor into their Gilead valuations Yeztugo's share gains in the growing HIV prophylaxis market ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the top low volatility healthcare stocks to buy now. In a report released on ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the most profitable biotech stocks to invest in now. TD Cowen analyst Tyler Van ...

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Now, it’s worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don’t miss out on the latest top 10 list, available when you ...

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 3% in the afternoon session after its long-acting HIV prevention injection, lenacapavir, received a recommendation for approval ...

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $113.03, denoting a -2.73% move from the preceding trading day.

Gilead Sciences (NASDAQ:GILD) stock fell 2.8% Monday morning following reports that Health and Human Services Secretary Robert F. Kennedy Jr. plans to dismiss all members of a key advisory panel that ...

Gilead Sciences (GILD) faces stock pressure as changes to the U.S. Preventive Services Task Force could impact PrEP drug ...

Gilead Sciences (GILD) stock gains as Needham upgrades the company to Buy from Hold citing its new HIV prevention injectable, ...

NEW YORK] Pheton Holdings, a Nasdaq-listed Chinese health care company, lost 90 per cent of its market value in a matter of ...

Gilead Sciences ( ($GILD) ) has risen by 7.31%. Read on to learn why. Gilead Sciences has seen a notable increase in its ...